List of Biotech, Pharmaceutical & Life Sciences companies in Virginia - 77

Aclairo's experience as FDA supervisors, reviewers, and industry strategists has forged a unique comprehension of the product-specific complexities of pharmaceutical development. The Aclairo advantage is our experience-based approach to providing strategic, scientific and regulatory services. This has proven to be our greatest asset in focusing and streamlining our clients' development efforts, reducing both time and costs.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.

Aditxt is a social innovation platform. Every year, billions of individuals face health challenges such as autoimmune diseases, misdiagnosis, infectious diseases, organ failure, reproductive health issues, malnutrition, cancer, as well as barriers to accessing healthcare. Innovations with immense potential to address critical healthcare challenges are all around us. Untapped innovations hold the key to transformative solutions. Socially owned and capitalized as  a Nasdaq listed company with a mission of discovering, developing and deploying promising health innovations. Now is the time to inspire and mobilize the social capital inherent in a global community of stakeholders to actively participate in the discovery, development, and implementation of health solutions that could benefit humanity.

Adovate develops novel drugs that target adenosine receptors involved in major diseases. These drug candidates have been created using our next-generation adenosine drug development platform, which enable design of patented compounds with favorable physiochemical characteristics and distribution kinetics that historically limited drugs acting against the adenosine receptors.

The mission of Amerimmune is to innovate in diagnoses and therapies of immune and allergic disorders.

Aretech is a world leader in developing advanced rehabilitation technologies for improving function and independence. We offer robotic body-weight support systems for a variety of therapy needs. Our technology includes ZeroG 3D, ZeroG, Ovation, and Luminaire. ZeroG 3D is a 3-Dimensional BWS System for multi-directional, unrestricted movement within a 3D workspace. The ZeroG Gait and Balance System is for gait and balance training along a custom designed ceiling track. Ovation is an interactive treadmill for patients up to 700 pounds to walk on a treadmill with motivating goals and metrics. Luminaire offers dynamic body-weight support over a slat-belt treadmill. All our products are hand-crafted in the United States and designed for durability with an emphasis on quality.

CancerLinQ, a ConcertAI initiative, is a health technology company focused on improving quality of care, advancing biomedical research, and improving health outcomes for all patients with cancer. CancerLinQ's products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. We are bilingual by design: fluent in both the language of oncology and technology. As a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research. Learn more at www.cancerlinq.org.

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines, microorganisms, and associated data for academia, industry, and government. With a history of scientific contributions spanning nearly a century, ATCC offers an unmatched combination of being the world’s largest and most diverse collection of biological reference materials and data, and is a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, partnerships, and people provide the global scientific community with credible, advanced, model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland. Visit atcc.org to learn more.

Beaufort is a global CRO built around one purpose — helping life science companies improve and save lives through the rapid development and commercialization of innovative products. Our shared interest and commitment to your success drives our entire organization to deliver best-in-class clinical trial services, regulatory strategy and planning, data and business analytics, data management and statistics, and quality services. We are: ◈ MedTech Focused - Industry-leading expertise to streamline your clinical development. ◈ IVD Specialists - Two decades of extensive diagnostic experience. ◈ Results Oriented - Guided by efficient and adaptive clinical trial management. ◈ Partnership Driven - 94% of clients rate Beaufort higher than other CROs Our experience includes: ◈ 500+ Regulatory Submissions including 510(k)s, PMAs, IDEs and CE-Marks ◈ 4,000+ Clinical Study Sites Around the Globe ◈ 1,000+ Clinical Trials Across a Wide Variety of Indications and Testing Platforms ◈ 2,600+ Clinical Professionals in Over 50 Countries See how Beaufort CRO can accelerate your medical innovation -- and put our experience to work for you.

TheBEI ResourcesRepository is a central repository, established by the National Institute of Allergy and Infectious Disease, that supplies organisms and reagents, such asSARS-CoV-2, to the broad community of microbiology and infectious diseases researchers.

BIO-CAT provides the very latest enzyme technology and custom formulations. Founded in 1988, our extensive range of products, from single-to-multi-enzyme blends, service various industrial, food, agriculture and other commercial markets. BIO-CAT is an FSSC 22000 certified facility in Virginia featuring state-of-the-art laboratories for scientific research, product development and on-site quality testing to better serve customers. BIO-CAT Microbials is an innovator in the field of biological solutions for a broad range of emerging and existing markets and industries. BIO-CAT Microbials is a GMP certified facility and a division of BIO-CAT, utilizing the latest enzyme technology in combination with microbes to produce products that are pioneering, more effective and of the highest quality for our customers’ applications.

Biopep Solutions Inc. is a privately owned, late pre-clinical stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. The Company’s lead product, BPS-001, is a heterogeneous biologic extract containing a known composition of multiple peptide and protein components. BPS-001 has the potential to treat a wide variety of cancers and diseases.

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

Biovista is a biotechnology company located in Charlottesville, Virginia, founded in 2005 by CEO Andreas Persidis. The company specializes in AI-driven drug repositioning and development services, aiming to enhance the efficiency of bringing new treatments to market. Biovista offers services that include drug repositioning, which identifies new therapeutic uses for existing drugs, and drug de-risking, which assesses and mitigates potential risks in drug development. The company also conducts disease cohort analysis to better understand specific patient populations and treatment strategies. Biovista develops its own drug repositioning programs across various therapeutic areas, including central nervous system disorders, diabetes and obesity, eye disorders, and oncology. The company employs advanced AI technologies to analyze large datasets, facilitating the discovery of novel applications for existing drugs. Biovista is actively involved in R&D projects, reflecting its commitment to advancing drug discovery through innovative approaches.

BrightSpec is an innovative life science tools company with a range of instruments that tap the power of molecular rotational resonance (MRR) spectroscopy. MRR enables the rapid, unambiguous molecular ID and quantitative analysis of mixtures, without separation, no chemometrics, and with no reference sample required. Not only can BrightSpec MRR complement other techniques such as Mass Spectrometry or NMR, in many cases MRR can solve problems not possible by these methods. For instance, MRR can easily distinguish between isomers (compounds with the same atoms but a different arrangement) or identify the exact site of deuteration of a molecule as well as quantify the number of each in the sample. BrightSpec is in the process of working with leading pharma, biotech, and academic players to develop breakthrough methods that will enable important advances in discovery. The company is also working with major chemical, oil & gas, consumer products, security, and environmental players to bring innovative solutions to these applied markets. The work is supported by research from a growing number of academic institutions as evidenced by a rising number of publications using BrightSpec instruments. BrightSpec builds on decades of federal and academic work in more than 110 research groups around the world. The technique was developed foremost in astrochemistry research. Using breakthrough technology developed by Brooks Pate at the University of Virginia, BrightSpec made this powerful technique of practical use by making the instrument significantly faster, cheaper, and easier to use. MRR spectra capture the unique set of rotational resonances, a fingerprint specific to a given molecular structure. These can be calculated theoretically based on quantum mechanics and are highly resolved. Isomers, isotopologues, diastereomers and enantiomers can be distinctly identified.

Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.

Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of QuitPak®, a patented treatment for smoking cessation, and a novel catheter lock solution to prevent clot formation in catheters. The Company is led by an experienced management team and Board of Directors, including Douglas Cary (President) a former Abbott Laboratories executing; Carl Schwan (CFO) a former CFO for two successful initial public offerings that raised $80 million; and Lester Crawford (Director), Former Commissioner of the U.S. Food and Drug Admininstration (FDA).

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. In the completed Phase 3 study, CEL-SCI studied patients who were newly diagnosed with locally advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine administered first, before they received the standard of care, which involved surgery followed by either radiation or chemoradiation. The Phase 3 study enrolled 928 patients. Our approach is unique because most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. After analyzing data from the Phase 3 study, we have better defined the target population for Multikine, which is locally advanced primary head and neck cancer patients with no lymph node involvement and with low PD-L1 tumor expression. In the Phase 3 study, we observed statistically significant survival in this target population, showing that Multikine cut the risk of death in half at five years vs control. Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Multikine is the trademark we have registered for this investigational therapy, and this proprietary name is subject to review by the FDA in connection with our future anticipated regulatory submission for approval.

Transformation. It's a word we hear a lot—the moment when a discovery leads to an innovation that fundamentally changes our world. There's a backstory to transformation—one that takes place in labs and research facilities by people who work tirelessly for years to reach that a-ha moment. Cerillo understands the passion, tenacity and investment that come before transformation. Our technology is laser-focused on helping you achieve greater efficiency and agility in your research. But more than that, it's designed to illuminate possibility by letting you view the same problem from new angles. Stratus, our portable plate reader, is helping scientists anticipate and creatively solve human challenges from the palm of their hand, giving them the freedom to take their work out into the world. And that's just the beginning. Our team is committed to constant innovation in our lab to make discovery in your lab easier. Think of us as the proactive lab partner you didn't know you needed, clearing the way for you to reach that transformational moment that changes the world for good.

Corning is one of the world's leading innovators in materials science, with a 170+ year track record of life-changing inventions. Corning applies its unparalleled expertise in glass science, ceramics science, and optical physics along with its deep manufacturing and engineering capabilities to develop category-defining products that transform industries and enhance people's lives. Corning succeeds through sustained investment in RD&E, a unique combination of material and process innovation, and deep, trust-based relationships with customers who are global leaders in their industries. Corning's capabilities are versatile and synergistic, which allows the company to evolve to meet changing market needs, while also helping our customers capture new opportunities in dynamic industries. Today, Corning's markets include optical communications, mobile consumer electronics, display technology, automotive, and life sciences vessels. Corning's industry-leading products include damage-resistant cover glass for mobile devices; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for state-of-the-art communications networks; trusted products to accelerate drug discovery and delivery; and clean-air technologies for cars and trucks. Terms of Use: http://ow.ly/ObPiI

DYNEX Technologies Inc. is a pioneer in the design and manufacturing of fully automated ELISA and Chemiluminescence microplate technology. Our fully automated line of ELISA testing instruments and consumables continue to raise the bar in laboratory optimization and efficiency. With over 8,500 instruments worldwide, DYNEX® offers solutions with increasing levels of throughput to support laboratories of all sizes and specialties. Be assured that the DYNEX family of U.S. manufactured, ISO certified instruments, will remain a steady and reliable component to achieving optimal laboratory proficiency.

If it has to do with temperature measurement or calibration of temperature measurement equipment, EDL designs, engineers, manufactures,

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

Engineered BioPharmaceuticals, Inc. is a state-of-the-art biotechnology company focused on advancing dry powder pharmaceutical manufacturing and delivery through Atmospheric Spray Freeze Drying (ASFD) technology. Manufacturing dry powder pharmaceuticals using the ASFD process offers many possibilities including increased stability and shelf life of drug formulations, ability to store at room temperature, reduced weight and bulk, and the ability to facilitate the development of novel self-administration methods of delivery, such as nasal and pulmonary. A significant advantage of the ASFD process compared to its competitors is that it allows pharmaceutical powders to be "engineered" for a wide variety of final use applications. A specific final particle size is easily achieved by adjusting the droplet diameter via the spray nozzle. In addition, the density, and thereby the aerodynamic size, can be adjusted independent of the geometric diameter by altering the starting solute concentration. With our population demanding sophisticated therapeutics to extend life expectancy and improve quality of life, contrasted with the dire need to reduce spiraling healthcare costs, there is enormous pressure and opportunity for the pharmaceutical industry to embrace new technologies that answer the call. We are excited about the innovative work taking place at eBio to advance the field and look forward to the opportunity to use ASFD technology to impact the future of medicine.

Experimental Pathology Laboratories, Inc. (EPL®) is recognized internationally for its ability to meet the needs of the scientific community and the challenges of preclinical safety testing with high quality, on-time histopathology services. EPL’s wholly owned subsidiary, Aclairo, has seamlessly integrated their efforts with our core histopathology services to provide expert toxicological, pharmacological, DMPK and clinical pharmacology support. Together, we are Experienced Proven Leaders.

GENETWORx Laboratories was formed with the central focus of impacting the lives of our people by empowering their physicians with information. Now, GENETWORx is dedicating our focus to fighting back against COVID-19. GENETWORx' COVID-19 test is the gold standard due to being 10% accurate, with 10% sensitivity and specificity. GENETWORx's COVID-19 test detects infection in the earliest stage, with a long turnaround time. Once a sample has been received in our laboratory, the prescribing physician will have the result via GENETWORx's portal within 10 business days. GENETWORx provides ongoing COVID-19 testing so that states, employers and organizations can continue or again open their operations with a safe and healthy workforce. We are completing thousands upon thousands of tests a day, and are growing to ensure that everyone in the USA can be tested and return to work. GENETWORx has met the Federal and State licensure requirements to operate in all 50 states. • CAP Number: 8732425 • CLIA Number: 49D2060159 Learn more about COVID-19 Testing: https://www.genetworx.com/faqs Our core values: • Personalized patient-centric care • Translating science into actionable intelligence • Supporting doctors and pharmacists in their delivery of top-quality Personalized Medicine • Enabling cost-effective health care • Preserving patient privacy

G3 leverages molecular profiles of human health and disease to develop life changing diagnostics and therapeutics.

GlycoMantra is a biologics company developing novel therapeutics for unmet medical needs in metastatic castration-resistant prostate cancer, NASH liver disease, and other diseases.

immunArray is a molecular diagnostics company that is engaged in developing novel blood-based tests to support the diagnosis and management of autoimmune diseases.

INCOGEN is a biotechnology company that specializes in genomics research and services.

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorder and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in 37 countries worldwide. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit: • Focus on patient needs to drive decisions • Seek the wisdom of the team • Believe that people’s actions are well intended • Care enough to coach • See it, own it, make it happen • Demonstrate honesty and integrity at all times

Whether you conduct primary research on allergens, develop diagnostic systems, or create products to alleviate environmental and food allergies, you need expertise in action. And that’s exactly what InBio delivers, across everything from highly purified allergens and advanced test kits, to environmental and food allergen testing, to contract research for specialized needs. • Broad product catalog • Deep scientific background • Ongoing commitment to R&D • Well-documented subject-matter expertise • Direct contact with our scientific team • Flexible, collaborative relationships

Jeeva Clinical Trials Inc. specializes in decentralized clinical trial solutions, offering a unified SaaS platform that enhances global patient engagement and streamlines trial operations. The company utilizes AI-powered tools and modular technology to support efficient trial management, allowing sponsors and medical centers to conduct studies under a single login. Their services include decentralized and hybrid trial solutions, patient recruitment and retention tools, and comprehensive clinical data management. Jeeva's platform features a next-generation Clinical Trial Management System (CTMS) for real-time oversight and protocol adjustments. The company prioritizes security and compliance, adhering to HIPAA, GDPR, and other regulatory standards. Jeeva has successfully implemented its solutions in oncology trials, achieving significant improvements in patient enrollment and data accuracy. They also support academic research, reducing costs and administrative burdens for campus-based studies. With a focus on scalability and workflow standardization, Jeeva provides a patient-centric approach to modern clinical trials.

Kaléo is dedicated to inventing, manufacturing & commercializing life-transforming products that protect and empower patients and families to live fuller, bolder lives.

KeifeRx is an emerging clinical-stage biopharmaceutical company developing novel and optimized, low dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative and immune diseases.

KeViRx, Inc. is a preclinical stage pharmaceutical company headquartered in Charlottesville, VA. We are developing small molecules drugs that treat microvascular leakage and inflammation, pathologies that are the basis for many diseases, including cancer and respiratory disease. We are now entering IND-enabling studies for pulmonary microvascular leakage and inflammation during acute lung injury. Our lead asset, KVX-053 has potent anti-inflammatory and immunomodulatory effects. In preclinical models, KVX-053 reduces lung injury scoring & the biomarkers of lung injury, inflammation & proinflammatory cytokine release, & immune cell infiltration into the lung. KVX-053 also improves lung function after lung injury.

Baculovirus protein expression services

For more than 100 years the LewisGale name has been synonymous with high-quality, compassionate healthcare. Today, our unwavering commitment to our patients ranks us as one of the top hospitals in Virginia and the nation for quality of care including patient safety, patient satisfaction and health outcomes. Our growing integrated network of care includes four hospitals, six outpatient centers, two cancer centers and 700 physicians at more than 160 affiliated locations stretching from Alleghany Highlands and Rockbridge County to the Roanoke and New River Valleys. LewisGale Regional Health System is part of HCA Healthcare. HCA Healthcare has been continually named a World's Most Ethical Company by Ethisphere since 2010. In 2019, HCA Healthcare spent an estimated $3.7 billion in cost for the delivery of charitable care, uninsured discounts, and other uncompensated expenses.

LumaCyte’s advanced real-time bioanalytics platform, Radiance®, is a label-free, single cell approach for quantitative characterization of innate cellular responses, without the need for antibody or genetic labeling. This revolutionary technology utilizes Laser Force Cytology™ (LFC) to measure subtle phenotypic changes based purely on the intrinsic biophysical and biochemical properties of cells in response to their environment and/or treatment.

With proven research capabilities across disciplines and applications, we develop technologies for mission-driven organizations, bringing high-impact solutions to life. From small-scale prototypes to market-ready products, our scientists and engineers leverage biotechnology, advanced materials, and engineered systems to create solutions that save time, save money, and save lives. We collaborate with the best companies, universities, and government labs in the world to explore the most promising new ideas and deliver transformative technologies to align with our customers' expectations. Our robust network of manufacturers, suppliers, licensees, and distributors extends our global impact. Biotechnology We solve complex healthcare challenges through applied R&D in wound mitigation, drug delivery, biosensors and wearables, point-of-care diagnostic platforms, and medical training tools. Core competencies: - Delivering the power of laboratory diagnostics to the field including POC ELISAs, dissolvable capture swabs, and automated spectrometry systems - Bio-interfacing technologies including nanofiber-based electrodes and quantitative ultrasound - Engineering biological responses to enhance wound care including adhesion barriers and nanofiber dressings for localized pain relief - Leveraging nanotechnology for advanced pharmaceutical design - Creating medical simulation tools for bleeding control and joint reduction Materials and Systems We specialize in cutting-edge research, development, and analysis for a wide range of applications including protective coatings, textiles, composites, electromagnetics, and corrosion monitoring and prevention. Core competencies: - Military-specific materials development - Advanced manufacturing techniques such as additive manufacturing and precision machining - Chemical and biological defense - Performance evaluation and testing - Lightweight materials and structures - Asset monitoring and non-destructive evaluation

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mission: Managing Complexity. Improving Lives. Values: Quality, Integrity, Service Principal Executive Office: Mallinckrodt plc Damastown Industrial Estate Mulhuddart, Dublin 15 Ireland U.S. Headquarters: 675 McDonnell Blvd. St. Louis, MO 63042 USA Website: www.mallinckrodt.com Stock Ticker: MNK Corporate Blog: http://blog.mallinckrodt.com/ Careers Website: www.mallinckrodt.com/careers Investor Relations: http://www.mallinckrodt.com/investors

Nexilico is an early-stage biotechnology startup that employs the power of computational biology and AI to address challenging problems in medicine and biotechnology. As a pioneer in the next generation in silico microbiome technologies, Nexilico advances scientific understanding about the role of microbiomes in health and disease and leverages that information to develop novel microbiome-based technologies

NEXT Bio-Research, Services continues a 23 year history in providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors. We also provide medical testing services to physicians using state-of-the-art platforms. NEXT Bio-Research Services was founded by three long standing colleagues who have worked together these past 23 years and collectively represent more than 100 years’ experience in life science technologies. NEXT Bio-Research Services is focused in (1) clinical testing using molecular and biochemical techniques; (2) molecular genetics of pharmacogenomics and cancer; (3) contract research in drug discovery and development with private sector customers; and (4) laboratory support of human clinical trials. We function as an extension of your own laboratory in helping you to bring their products from discovery to market. Our laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) act and our contract research services are offered individually or can be integrated to support product development from discovery to market with full regulatory support under FDA GLP Guidelines 21 CFR 58.

NImmune is a late-stage precision immunology biopharmaceutical company that develops best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by advanced computational modeling and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. NImmune’s clinical development pipeline includes omilancor, a Phase 3-ready lead clinical candidate targeting LANCL2, an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023.

Develop DNA nanostructures

Accelerating Sustainable Agriculture Millions of researchers, agricultural companies, and farmers globally are working hard to create solutions that reduce farming's environmental impact. We believe digitalization will be the major driver in this process. Our digital phenotyping solutions capture crop data and turn it into actionable insights, accelerating the transition to sustainable agriculture. Phenotyping is fundamental to the development of new agrochemicals, new plant varieties, and farming itself. Phenotyping is traditionally done visually or destructively – it's time consuming, expensive, and imprecise. Our mission is to automate the process, make the data actionable, and enable our clients to deliver new agrochemicals and crops faster than ever before. We empower seed companies, crop protection companies, and indoor farms around the world in transforming their phenotyping processes into digital, agile and efficient development pipelines. Combining our expertise in sensors, automation, and data analysis with our clients' know-how, we're driving transformation. Join Phenospex Join us to tackle complex problems at the intersection of high tech and nature. Your work will impact sustainable agriculture through our innovative digital phenotyping technology. Be part of a team that advances technology and makes a real difference. Our Culture We foster an open and informal culture, with transparent communication about company performance. We value your freedom, commitment, and responsibilities, owning and adapting processes to serve our goals better. Our Team You'll join an ambitious, intelligent, and diverse group of international professionals who believe they can change the world. We enjoy spending time together outside of work, engaging in activities like bouldering, wakeboarding, and cycling, fostering strong camaraderie and community. Apply If you're passionate about shaping the future of agriculture: https://phenospex.com/careers/

Qnovia has created an inhaled drug delivery platform to deliver a broad range of pharmaceuticals.

Founded in 2018, Quoin is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. The company plans to establish a sales infrastructure to commercialize its products in both U.S. and Europe and seeks to enter into strategic licensing partnerships for all other territories. We are dedicated to finding unique solutions for rare and orphan indications and will continue to expand our pipeline of products to address the unmet needs of underserved patient populations. To learn more about Quoin Pharmaceuticals please visit our website: www.quoinpharma.com

ReAlta Life Sciences is a biotech company that focuses on rebalancing the inflammatory response to address life-threatening acute inflammatory and rare diseases with their EPICC peptides based on the human astrovirus research.

RECKITT BENCKISER GROUP PLC is a Consumer Goods company that offers a wide range of household, healthcare, and hygiene products.

Response Pharmaceuticals, Inc, is a clinical-stage therapeutic development company focused on developing treatments for weight management and metabolic disease. Our initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments.

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.

RetiVue LLC is focused on providing novel, high definition retinal imaging technology with a wider field of view to help document early eye disease to help needless blindness. The RetiVue WF Desktop and RetiVue WF Portable are the first affordable non-mydriatic widefield retina cameras for everyone from babies to adults. Our revolutionary design allows you to image up to ten times more of the retina than competing devices. Point and shoot automatic image capture gives you perfect images of the eye every time, regardless of level of expertise. Our company strives to become the de-facto standard equipment used for eye screening, capturing higher quality images, while simultaneously maintaining device affordability and simplifying ease of use.

Revivicor Inc.is a regenerative medicine company focused on applying animal biotechnology platforms to provide high-volume, human-compatible, alternative tissue source for treating human degenerative disease. The company produces pig islets, organs, and medical devices aimed at human clinical applications.

RIVANNA® is elevating global standards of care through the development and commercialization of world-first imaging-based medical technologies, including BoneVision™ Multi-Probe Multi-Angle Image Acquisition, BoneEnhance® Multi-Frequency Image Reconstruction, and SpineNav3D™ AI-Enabled Spine Recognition. RIVANNA's complete clinician-assistance solutions improve decision-making, workflows, health outcomes, and patient satisfaction. Headquartered in Charlottesville, VA, RIVANNA is privately held and operates an FDA-registered and ISO 13485:2016 certified manufacturing facility. For more information, visit rivannamedical.com.

Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF).

Sciengenix Laboratory Inc in Richmond offers a wide range of services for your health and wellbeing.

Serpin Pharma is a biotech company that develops targeted therapeutics to enhance the body's natural immune response, reducing inflammation and restoring immune balance.

Slate Bio is a Virginia-based biopharmaceutical company that develops and commercializes T cell therapies for the treatment of autoimmune and inflammatory diseases.

SoBran, Inc. is a provider of specialized services in bioscience, engineering, logistics, security, and mail screening solutions. Founded in 1987 by Amos-Leon' Otis, the company has grown from a small startup in Virginia to a recognized enterprise known for its innovation and service delivery. SoBran offers a variety of services tailored for government agencies, corporations, and universities. Their bioscience support includes laboratory operations and health monitoring. In engineering, they provide systems engineering management to enhance performance and meet industry standards. Their logistics services ensure efficient supply chain management, while their security services protect critical infrastructure. The SafeMail® solution is a key offering that focuses on secure mail handling to mitigate potential threats. With a strong client base that includes the National Institutes of Health and the Department of Homeland Security, SoBran has earned recognition for its quality and service. The company is ISO 9001:2008 certified and has been named a Black Enterprise Top 100 Company multiple times, reflecting its commitment to excellence.

Our vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of radiopharmaceuticals. www.sofie.com www.twitter.com/sofiebio www.instagram.com/sofiebio

Solar Biotech is a technology and bioproducts development start-up that utilizes biological systems and cutting-edge biomanufacturing technologies to develop and produce SynBio products through precision fermentation and state-of-the-art downstream processing technologies. Not a solar power company. The goal of the company is to become a global leader, provider of sustainable, microbial cell-based biomanufacturing technologies and services across different SynBio market segments, including the SynBio FoodTech segment. Recognising rising consumer trends for sustainable, traceable, healthier, and safer consumer products, Solar Biotech is committed to operating sustainably and to delivering the highest quality SynBio products available to clients worldwide.

Synthonics, Inc. is a privately-held specialty pharmaceutical company focused on the discovery and development of patentable drugs that incorporate our proprietary metal coordination chemistry. We bind metals to known pharmaceutical agents to create new products that are better absorbed and thus have greater therapeutic benefits than their predecessors. Although our chemistry has broad application, we're preliminarily focused on drugs, such as T3 (liothyronine) and levodopa, whose short half-life limits their clinical utility.

SYSTAAQ Diagnostic Products is one of the leaders in molecular diagnostics, offering a wide range of products and services in the field of molecular testing. We have a unique capacity in people and technology to provide innovative, cost-effective, timely and reliable solutions in biomedical research and laboratory diagnostics.

TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for the treatment of ocular surface disease in primary Sjögren’s Syndrome patients. Statistically significant improvement in both sign and symptom at two weeks was found. The trial compared vehicle and two doses of LacripepTM, a novel 19 AA peptide that is present in normal tears and deficient in all forms of dry eye. The peptide restores homeostasis to the ocular surface, in particular the barrier function of the corneal epithelium and normal function of sensory nerves at the corneal surface in preclinical animal models. Restoration of epithelial barrier function can be measured clinically as a decrease in corneal fluorescein staining while the improvement in sensory nerve function restores normal production of the components of tears: the aqueous via reinnervation of lacrimal glands, the lipid via reinnervation of meibomium glands and the mucin via reinnervation of goblet cells. Improvement in fluorescein staining and tear production (Schirmer tear test) are clinical ‘signs’ of ocular suface disease that have been used in the FDA approval of Xiidra and Restasis, respectively. Lacripep was discovered at the University of Virginia with NIH National Eye Institute funding as a naturally occurring fragment of the larger 119 AA protein, lacritin, in an unbiased screen for novel factors capable of addressing dry eye.

TECHLAB, Inc. is a leading developer and manufacturer of infectious disease diagnostics products worldwide. Since 1989, the company has offered a quality portfolio of diagnostic tests which now includes assays for C. difficile, respiratory pathogens, H. pylori, Campylobacter, Shiga toxin producing E. coli, protozoan parasites, and biomarkers of intestinal inflammation. TECHLAB is headquartered in Blacksburg, VA and manufactures its diagnostic tests in the United States at its state-of-the-art manufacturing facility in Radford, VA.

Medical & Aircraft Instruments

Virginia Commonwealth University School of Medicine is a medical school that provides education, healthcare services, and conducts research.

Dedicated to its motto, Ut Prosim (That I May Serve), Virginia Tech takes a hands-on, engaging approach to education, preparing scholars to be leaders in their fields and communities. As the commonwealth’s most comprehensive university and its leading research institution, Virginia Tech offers 215 undergraduate and graduate degree programs to 31,000 students and manages a research portfolio of $450 million. The university fulfills its land-grant mission of transforming knowledge to practice through technological leadership and by fueling economic growth and job creation locally, regionally, and across Virginia.

Zephyr AI uses large complex data and proprietary algorithms to discover new insights and opportunities for Personalized/Precision Medicine, Drug Discovery, Drug Rescue, and Clinical Decision Support. Zephyr AI partners with leading health systems, health insurance plans, and biotechnology pioneers to improve Quality, Outcomes and Costs.